Introduction {#s1}
============

Disinfection of drinking water is vital for the protection of public health since it greatly reduces pathogen risks and associated incidences of waterborne diseases ([@c18]) and is considered one of the major public health achievements of the 20th century ([@c11]). However, the powerful oxidants used during disinfection (e.g., chlorine or ozone) can react with natural and synthetic organic matter to inadvertently produce a multitude of potentially harmful chemicals, collectively known as disinfection by-products (DBPs) ([@c67]). Evidence suggests that many DBPs exhibit cytotoxic, genotoxic, mutagenic, teratogenic, neurotoxic, and potentially carcinogenic properties, and may consequently elicit various adverse health effects ([@c22]; [@c35]; [@c50]; [@c56]; [@c63]; [@c68]; [@c78]; [@c84]; [@c88]). The presence of toxic DBPs is a concern for legislators and suppliers of drinking water, and identifying the forcing agents for toxicity is a research priority for ensuring responsible water management that protects public health and the environment ([@c57]; [@c41]).

To date, a limited number of DBPs have been characterized, and only a small fraction of these have been evaluated toxicologically ([@c84]; [@c73]). Brominated DBPs (Br-DBPs) tend to display higher toxicity than their chlorinated analogs (Cl-DBPs) ([@c26]; [@c56]; [@c89]) and are readily produced through chlorination of bromide-containing source waters ([@c60]). This is common in coastal areas suffering from seawater intrusion ([@c86]), where bromide anions undergo rapid oxidation reactions with hypochlorous acid to produce hypobromous acid ([@c6]; [@c47]; [@c86]). Br-DBPs are also a dominant by-product in swimming pools using chlorinated seawater and may thus represent a concern for exposure routes other than drinking water ([@c47]). Notwithstanding the apparent differential risks, few studies have comprehensively evaluated or compared mechanistic molecular toxicity of different DBPs. There is consequently a pressing need for research aimed at identifying those by-products posing the greatest threat to humans and the environment and at understanding the molecular mechanisms leading to adverse health effects such as cancer ([@c31]; [@c56]).

The potential association of DBPs with urinary bladder cancer ([@c78], [@c79]) and colorectal cancer ([@c63]; [@c80]) is an area of high interest. Both are among the most common types of cancer globally and display increased incidences in developed countries that benefit from higher levels of water disinfection ([@c72]; [@c58]). The exact mechanism(s) leading to genotoxic and carcinogenic outcomes are still unclear but are believed to relate in some capacity to the production of reactive oxygen species (ROS) and the subsequent activation of oxidative stress pathways ([@c52]). Interestingly, other effects, such as alterations to immune function and inflammation, have also been associated with exposure to DBPs ([@c83]; [@c51]). However, despite a rather well-established relationship between inflammation responses and the development and progression of cancer ([@c16]; [@c87]; [@c33]), there have been limited mechanistic studies in this area in relation to DBPs. This clearly warrants further investigation, since chronic inflammation is known to generate ROS through a variety of mechanisms ([@c33]; [@c65]).

Transcriptomics is a molecular technique that can help elucidate underlying mechanisms of toxicity by quantifying expressional changes of various genes with known biological functions ([@c17]). Microarrays are particularly useful as an untargeted, or global, approach to gene expression profiling, yielding information for the entire set of genes expressed in a biological sample at a given time ([@c34]). Based on our limited knowledge of how DBP exposure elicits adverse health effects and ultimately cancer, there are significant benefits to be gained from using untargeted transcriptomics to explore chemical--gene interactions caused by DBPs.

The objective of the present study was to build on prior research to address the identified knowledge gaps. We characterized the effects of low concentrations of selected DBPs on global gene expression (GE) in normal nontransformed human enterocytes (FHs 74 Int) and used the generated GE profiles to identify affected toxicity signaling pathways through pathway enrichment analysis.

Methods {#s2}
=======

Disinfection By-Product Selection {#s2.1}
---------------------------------

We selected six brominated and two chlorinated DBPs: bromoacetic acid (BAA), bromoacetonitrile (BAN), 2,6-dibromo-*p*-benzoquinone (DBBQ), bromoacetamide (BAM), tribromoacetaldehyde (TBAL), bromate (${BrO}_{3}^{-}$), trichloroacetic acid (TCAA), and trichloroacetaldehyde (TCAL). The six Br-DBPs were chosen based on their known or modeled toxicity, representing classes of carbonaceous (C-DBPs) and nitrogen-containing DBPs (N-DBPs) ([@c55]). An example of the different toxicological characteristics expressed by representatives BAA and BAN is that both are cytotoxic and genotoxic, but additionally, BAN was shown in Chinese hamster ovary (CHO) cells to disrupt the cell cycle by what was suggested to be an M-phase black that generated aberrant cells with an abnormal number of chromosomes ([@c36]; [@c38]). These DBPs were detected in disinfected drinking waters ([@c81]; [@c67]; [@c93]). Conversely, the two Cl-DBPs were chosen for comparison due to their low overall cytotoxicity. In the case of TCAA, evidence for genotoxicity and mutagenicity is lacking, and there is limited weight of evidence for carcinogenicity, whereas TCAL has confirmed mutagenicity, genotoxicity, and carcinogenicity (reviewed in [@c66]). All of the selected DBPs are organic molecules, with the exception of the inorganic oxo-anion bromate.

Reagents {#s2.2}
--------

BAA, BAN, BAM, TBAL, sodium bromate, TCAA, TCAL, and neutral red (NR) solution \[0.33%, $3.3\; g/L$ in Dulbecco's phosphate-buffered saline (DPBS)\] were purchased from Sigma-Aldrich, and DBBQ was purchased from Apin Chemicals. All stock solutions were prepared in methanol (MeOH), stored at $- 20{^\circ}C$, and brought to room temperature immediately prior to exposure treatments. DMSO was avoided as a solvent because it can affect gene expression even at the low concentrations often used in toxicological testing ([@c40]; [@c74]), while evidence suggests MeOH is tolerable at slightly higher concentrations with lower impact on enzymatic activity ([@c10]) and reporter gene assays ([@c25]; [@c40]).

The cell culture medium was purchased from American Type Culture Collection (ATCC). PBS, epidermal growth factor (EGF), fetal bovine serum (FBS), and nonessential amino acids were purchased from Thermo Fisher Scientific.

Cell Culture {#s2.3}
------------

Homo sapiens small intestine normal cells (FHs 74 Int) (CCL-241™; ATCC) were maintained in sterile $175{\text{-}{cm}}^{2}$ culture flasks (Corning, catalog no. 431,080) at 100% humidity, 37°C, and 5% ${CO}_{2}$. Cells were maintained in Hybri-Care medium (ATCC® 46-X™; ATCC) supplemented with $30\text{ \ ng}/{mL}$ EGF (90%) and 10% FBS and subcultured twice a week upon reaching $70–85\%$ confluence to maintain exponential growth phase using warm PBS (pH 7.4; Invitrogen) and 0.25% trypsin/ethylenediaminetetraacetic acid (EDTA) solution (Invitrogen).

Cytotoxicity Assay {#s2.4}
------------------

The cytotoxicity assays were performed using neutral red dye uptake (NRU) as an indicator of cell viability. NRU is one of the most widely applied *in vitro* cytotoxicity assays with numerous biomedical ([@c12]) and environmental applications ([@c44]; [@c70]). The assays were carried out using a previously described method for Caco-2 cells ([@c39]) with minor modifications for FHs 74 Int cells. Briefly, each of the tested DBPs was prepared as a concentrated stock in methanol (MeOH) up to a concentration of $1\; M$ or, in the case of DBBQ, to the limit of solubility ($\sim 0.25\; M$). On day 1 of the assay, plates were seeded at a density of $1 \times 10^{5}$ per well ($100\;\mu L$) in clear, sterile, flat-bottom 96-well microtiter plates (Greiner Bio-One CELLSTAR®; catalog no. 655-180), using PBS (pH 7.4; Invitrogen), 0.25% (wt/vol) trypsin/EDTA (Invitrogen) solution and growth medium (Hybri-Care medium) supplemented with $30\text{ \ ng}/{mL}$ EGF (90%, Thermo Fisher Scientific) and 10% FBS (Gibco). Eighteen hours later, the growth medium was removed by use of a vacuum aspirator, and wells were washed twice with $150\;\mu L$ of warm (37°C) PBS (pH 7.4). The assay medium, spiked with serially diluted DBPs, was added into the test wells to a total volume of $100\mspace{9mu}\mu L$ per well. After $4\; h$ of incubation at 37°C and 5% ${CO}_{2}$, cells were again washed with PBS ($2 \times$), $100\;\mu L$ of NR solution (0.33%, $3.3\; g/L$ in DPBS) was added and the plate incubated for $1\; h$. Finally, the NR solution was aspirated from the wells, cells were gently washed with warm PBS ($150\;\mu L$ per well), $150\;\mu L$ of NR desorbing fixative (50% EtOH/$H_{2}O$, 1% acetic acid) was added, and the plate was incubated for 5 min at room temperature. Absorbance was measured at $540\text{ \ nm}$ using a FLUOstar Omega® (BMG LABTECH) plate reader.

A cytotoxicity concentration--effect curve was generated using FHs 74 Int cells for each of the DBPs combining the data from all the individual runs ($n = 12$; a minimum of two individual runs on two separate days) ([Figure 1](#f1){ref-type="fig"}). Absolute absorbance values were converted to percent mean absorbance of untreated cell control wells (i.e., percent negative control) by first subtracting the mean background absorbance from the absolute absorbance value of each test well, then dividing the resulting value by the mean absorbance of the negative control, and finally multiplying by 100. Data were normalized in GraphPad Prism for Windows (version 6.05; GraphPad) using the program's Normalize function to standardize slight fluctuations between each run, and the percentages of negative control values were plotted against the log concentration (M). The median inhibition concentrations ($\text{IC}_{50}s$) for each of the DBPs were then calculated using [Equation 1](#d1){ref-type="disp-formula"} in GraphPad Prism 6.05 for Windows, anchoring the bottom constraint to 0% and the top to 100%. $$\%\text{ \ effect} = \text{bottom} + {\langle\frac{\text{top} - \text{ \ bottom}}{1 + 10\left\{ {\left\lbrack {\log\,\left( \text{IC}_{50} \right) - \log\,\left( x \right)} \right\rbrack \times \text{slope}} \right\}}\rangle}$$

![FHs 74 Int acute cytotoxicity \[$4\text{-}h$ neutral red dye uptake (NRU) test; $n = 12$\] concentration--effect curves for: (A) bromoacetic acid (BAA), bromoacetonitrile (BAN), and tribromoacetaldehyde (TBAL); (B) bromoacetamide (BAM), bromate, and dibromobenzoquinone (DBBQ); (C) trichloroacetic acid (TCAA); and (D) trichloroacetaldehyde (TCAL), presented as percent negative control (unexposed cells). Each point is the average of two to three independent runs on separate $\text{days} \pm \text{standard\  \ deviation}$. Calculated 10% inhibitory concentration ($\text{IC}_{10}$) values from these concentration--effect curves are presented in [Table 1](#t1){ref-type="table"}.](ehp-127-117006-g001){#f1}

The $\text{IC}_{10}$ value was calculated from those parameters by use of [Equation 2](#d2){ref-type="disp-formula"}: $$\log\,\left( \text{IC}_{10} \right) = \log\,\left( \text{IC}_{50} \right) - \left\lbrack \frac{\,\log\left( {\frac{\text{top} - \text{ \ bottom}}{10 - \text{bottom}} - 1} \right)}{\text{slope}} \right\rbrack$$

The $\text{IC}_{10}$ values for all eight DBPs obtained with FHs 74 Int cells in this study were compared to previously published $\text{IC}_{50}$ values in CHO cells (Table 5 in [@c84]) by correlation analysis \[Pearson Product Moment Correlation in SPSS Statistics for Windows (version 22; IBM Corporation)\].

Exposure and RNA Preparation {#s2.5}
----------------------------

FHs 74 Int cells (passages 3--7) were seeded in 6-well plates at a density of $1 \times 10^{6}$ per well $24\; h$ prior to treatment with the DBPs. Each well received an $\text{IC}_{10}$ concentration ([Table 1](#t1){ref-type="table"}) of test DBP or vehicle control, in duplicate, and was incubated at 37°C for $4\; h$. The $4\text{-}h$ treatment time was selected empirically based on experiments on the induction of genomic DNA damage by DBPs in CHO cells. That data demonstrated that a $4\text{-}h$ period allowed for the induction of DNA damage before the effect of DNA repair was observed ([@c37]). In addition, the $4\text{-}h$ exposure time was established in other studies on the toxic mode of action by DBPs by use of CHO ([@c19]; [@c36]) and FHs 74 Int cells ([@c52]). Finally, using CHO cells, the $4\text{-}h$ treatment period was established as a standard procedure to determine genomic DNA damage across a wide range of DBP chemical classes ([@c84]).

###### 

Equipotent 10% inhibitory concentration ($\text{IC}_{10}$) values and numbers of differentially expressed genes (DEGs) identified for the tested disinfection by-product (DBP).

Table 1 lists DBP in the first column; the corresponding values for log IC sub 10 in molar and IC sub 10 in molar are listed in the adjacent columns. Further, the number of D E Gs for all FCs (p less than or equal to 0.05 and p less than or equal to 0.01) and FC greater than or equal to 1.2 (p less than or equal to 0.01) are listed in the other columns.

  DBP               Log ($\text{IC}_{10}$) (mol/L) ($\text{mean} \pm \text{SE}$)   $\text{IC}_{10}$ (mol/L)   No. of DEGs                     
  ----------------- -------------------------------------------------------------- -------------------------- ------------- ----- ----- ----- -----
  BAA               $- 5.59 \pm 0.09$                                              $2.5 \times 10^{- 6}$      2,612         450   417   179   238
  BAN               $- 5.83 \pm 0.06$                                              $1.5 \times 10^{- 6}$      2,614         451   406   176   230
  DBBQ              $- 4.34 \pm 0.03$                                              $4.6 \times 10^{- 5}$      2,614         356   334   156   178
  BAM               $- 4.91 \pm 0.07$                                              $1.2 \times 10^{- 5}$      2,610         381   367   164   203
  ${BrO}_{3}^{-}$   $- 3.38 \pm 0.07$                                              $4.2 \times 10^{- 4}$      2,615         398   370   157   213
  TBAL              $- 5.72 \pm 0.08$                                              $1.9 \times 10^{- 6}$      2,620         412   383   170   213
  TCAA              $- 1.88 \pm 0.09$                                              $1.3 \times 10^{- 2}$      2,604         266   201   82    119
  TCAL              $- 2.19 \pm 0.03$                                              $6.5 \times 10^{- 3}$      2,599         269   175   67    108

Note: $\text{IC}_{10}$ values were calculated from the concentration--effect curves presented in [Figure 1](#f1){ref-type="fig"}, based on the cytotoxicity assay in FHs 74 Int cells \[$4\text{-}h$ neutral red dye uptake (NRU) test; $n = 12$). DEGs obtained by rank product analysis (1,500 permutations, $n = 2$). BAA, bromoacetic acid; BAM, bromoacetamide; BAN, bromoacetonitrile; ${BrO}_{3}^{-}$, bromate; DBBQ, dibromobenzoquinone; SE, standard error; TBAL, tribromoacetaldehyde; TCAA, trichloroacetic acid; TCAL, trichloroacetaldehyde.

The wells were then washed with warm PBS and cells were lysed with QIAzol (Qiagen) ($1\;{mL}$ per well), collected in $1.5\text{-}{mL}$ microcentrifuge tubes, and frozen ($- 20{^\circ}C$) overnight. The top aqueous layer was then used for RNA extraction using an RNeasy Mini Kit (Qiagen) following the manufacturer's protocol with minor modification. In brief, the cell lysates in $1.5\text{-}{mL}$ tubes were brought to room temperature ($15–25{^\circ}C$), homogenized by vortexing for 1 min, and placed on the benchtop for 5 min. Chloroform \[$200\;\mu L$, molecular biology (MB) grade, Sigma-Aldrich\] was added to each tube, which was then shaken vigorously for $15\; s$ and placed on the benchtop for 2--3 min. The lysates were then centrifuged for 15 min at $12,000 \times g$ at 4°C to ensure efficient phase separation. A $500\text{-}\mu L$ aliquot of the top aqueous layer of each sample was then carefully transferred to a fresh, nuclease-free, $1.5\text{-}{mL}$ microcentrifuge tube, to which $750\;\mu L$ of 100% ethanol (MB grade, Sigma-Aldrich) was added and mixed thoroughly by pipetting up and down several times. Each sample ($700\;\mu L$) was then immediately loaded onto the RNeasy Mini spin column and centrifuged at $\geq 8,000 \times g$ for $15\; s$ at room temperature. The flow-through was discarded and the process repeated until all of the sample was processed. Next, $500\;\mu L$ of Buffer RPE (from the RNeasy Mini Kit) was added to each spin column and centrifuged at $\geq 8,000 \times g$ for $15\; s$ to wash the column, and the flow-through was discarded. Another $500\;\mu L$ of Buffer RPE was added to each spin column and centrifuged at $\geq 8,000 \times g$ for 2 min to dry the spin column membrane. The spin column was placed into a fresh $2\text{-}{mL}$ collection tube and centrifuged at full speed for 1 min. Finally, each spin column was transferred into a fresh $1.5\text{-}{mL}$ microcentrifuge tube, $20\;\mu L$ of nuclease-free water was pipetted directly onto the spin column membrane, and the column was centrifuged at $\geq 8,000 \times g$ for 1 min to elute the RNA. This final process was repeated with an additional $20\;\mu L$ of nuclease-free water, for a total of $40\;\mu L$ of total RNA extract.

The yield and purity of extracted RNA was measured spectrophotometrically using a BioSpectrometer® (Eppendorf South Pacific) equipped with a Traycell microliter measurement cell (Hellma GmbH & Co. KG), and RNA integrity was determined at the Ramaciotti Centre for Genomics using a 2100 Bioanalyzer (Agilent Technologies) prior to hybridization and microarray sample analysis ([Table 2](#t2){ref-type="table"}).

###### 

Summary of RNA yield ($\text{ng}/\mu L$), purity (absorbance ratios, A260/A280 and A260/A230), and RNA integrity number (RIN).

Table 2 lists RNA extract I D in the first column; the corresponding values for RNA concentration, A260 or A280, A260 or A230, and R I N are listed in the other columns.

  RNA extract ID       RNA concentration ($\text{ng}/\mu L$)   A260/A280   A260/A230   RIN
  -------------------- --------------------------------------- ----------- ----------- ------
  BAA 1                69.9                                    2.03        2.01        9.5
  BAA 2                47.5                                    1.97        2.11        9.9
  BAN 1                66.9                                    1.99        2.08        9.1
  BAN 2                64.8                                    1.88        1.95        10.0
  DBBQ 1               58.3                                    2.04        2.24        8.4
  DBBQ 2               62.7                                    2.00        2.10        9.6
  BAM 1                72.7                                    2.00        2.20        8.5
  BAM 2                57.4                                    2.06        1.96        9.9
  ${BrO}_{3}^{-}$ 1    66.9                                    2.00        2.25        9.6
  ${BrO}_{3}^{-}$ 2    79.2                                    1.95        2.07        9.7
  TBAL 1               54.8                                    2.08        2.12        9.5
  TBAL 2               55.8                                    1.98        1.90        9.6
  TCAA 1               67.6                                    1.95        2.04        9.2
  TCAA 2               63.7                                    2.10        2.01        9.4
  TCAL 1               62.1                                    1.97        2.05        9.4
  TCAL 2               58.9                                    2.07        2.03        9.4
  Negative control 1   47.8                                    2.06        2.12        9.7
  Negative control 2   63.4                                    1.92        2.11        9.5

Note: BAA, bromoacetic acid; BAM, bromoacetamide; BAN, bromoacetonitrile; ${BrO}_{3}^{-}$, bromate; DBBQ, dibromobenzoquinone; TBAL, tribromoacetaldehyde; TCAA, trichloroacetic acid; TCAL, trichloroacetaldehyde.

Microarray Transcriptomics and Statistical Data Analysis {#s2.6}
--------------------------------------------------------

The RNA extracts were analyzed using HumanHT-12 v4 Expression BeadChip arrays (Illumina). Hybridization and scanning were performed at the Ramaciotti Centre for Genomics with the supplied total RNA extracts. The raw fluorescence data was then transformed using the preprocessing variance stabilization algorithm ([@c43]), base-2 log transformation, and quantile normalization using the lumi package in the Bioconductor application suite (version 3.2) for R statistical programming language (version 3.5, R Development Core Team) ([@c21]; see Supplemental Material for the transformed microarray expression data). Ultimately, sets of statistically significant differentially expressed genes (DEGs) for each sample--control pair ($n = 2$) were identified with the Multiple Experiment Viewer (MeV) suite (version 4.90; The Institute for Genomic Research) for Windows ([@c69]) using rank product algorithm ([@c7]) set to 1,500 random permutations. DEGs with $p \leq 0.01$ and fold change (FC) $\geq 1.2$ were considered statistically significant and were further used in biological context analysis using pathway enrichment.

### Confirmatory quantitative real-time polymerase chain reaction. {#s2.6.1}

For comparison, the expression of the gene heme oxygenase 1 (*HMOX1*) was analyzed by quantitative real-time polymerase chain reaction (qPCR) in a parallel set of experiments with the same concentrations of DBPs and exposure durations. We selected to perform the confirmatory real-time qPCR on *HMOX1*, which: *a*) was detected consistently in a quantitative manner in our microarray experiments for all tested DBPs; *b*) has an established role in the response to oxidative stress ([@c59]); and *c*) was previously shown to be dysregulated in response to inflammation in mice ([@c75]). Briefly, we exposed the FHs 74 Int cells to the selected DBPs and extracted total RNA using the methodology described earlier in this study; we then reverse transcribed $500\text{ \ ng}$ of the total RNA using the iScript™ cDNA Synthesis Kit (Bio-Rad) and amplified it on a CFX96 Touch™ Real-Time PCR System (Bio-Rad) using iTaq™ Universal SYBR® Green Supermix (Bio-Rad) per the manufacturer's instructions under the following conditions: initialization $95{^\circ}C/60\; s$, followed by 44 cycles of denaturation $95{^\circ}C/15\; s$, annealing $59{^\circ}C/20\; s$, and extension $72{^\circ}C/20\; s$. Next, we transformed the resulting raw data of triplicate cycle threshold values into relative expression quantities considering the primer amplification efficiencies (E; $90\% < E < 110\%$) and normalized them using expression values for the ribosomal protein L27 (RPL27) using the method described in Pfaffl ([@c54]), yielding normalized relative quantities (NRQs). These are shown as the mean values ($n = 3$) of a minimum of two repeat experiments ([Figure 2](#f2){ref-type="fig"} and [Table 3](#t3){ref-type="table"}). Finally, we determined the statistical significance ($p \leq 0.05$) of the resulting NRQ values by ordinary one-way analysis of variance with Dunnett's multiple comparison correction method in GraphPad Prism (version 7.05; GraphPad). For comparison, the qPCR NRQ values are equivalent to the FC values obtained from the microarray analysis ([Figure 2](#f2){ref-type="fig"}).

![Gene expression levels of heme oxygenase 1 (*HMOX1*) following exposure to equipotent concentrations of eight disinfection by-products (DBPs) obtained using quantitative real-time polymerase chain reaction (qPCR) \[expressed as $\log_{2}\text{-\ normalized}$ relative quantities ($\log_{2}\text{NRQ}$); $n = 3$\] and microarray analysis \[expressed as $\log_{2}$ fold changes ($\log_{2}\text{FC}$); $n = 2$\]. Note: BAA, bromoacetic acid; BAM, bromoacetamide; BAN, bromoacetonitrile; ${BrO}_{3}^{-}$, bromate; DBBQ, dibromobenzoquinone; TBAL, tribromoacetaldehyde; TCAA, trichloroacetic acid; TCAL, trichloroacetaldehyde.](ehp-127-117006-g002){#f2}

###### 

Gene expression levels of heme oxygenase 1 (*HMOX1*) following exposure to equipotent concentrations of eight disinfection by-products (DBPs) obtained using quantitative real-time polymerase chain reaction (qPCR) and microarray.

Table 3 lists chemicals in the first column; the corresponding NRQ, log sub 2 NRQ, and p values for qPCR are listed in the adjacent columns. Further, values for FC, log sub 2 FC, and p values for microarray are listed in the other columns.

  Chemical          qPCR   Microarray                                     
  ----------------- ------ ------------ --------------- ------ ---------- ------------
  BAA               0.33   $- 1.61$     0.0092          0.50   $- 1.00$   $< 0.0001$
  BAN               1.47   0.56         0.0006          0.44   $- 1.18$   $< 0.0001$
  DBBQ              3.28   1.72         $< 0.0001$      3.58   1.84       0.0002
  BAM               8.75   3.13         $< 0.0001$      2.49   1.32       0.0014
  ${BrO}_{3}^{-}$   2.43   1.28         0.0001          2.27   1.19       0.0007
  TBAL              3.41   1.77         $< 0.0001$      1.76   0.82       0.0016
  TCAA              1.06   0.09         ns ($> 0.05$)   4.22   2.08       $< 0.0001$
  TCAL              1.67   0.74         $< 0.0001$      3.87   1.95       $< 0.0001$

Note: BAA, bromoacetic acid; BAM, bromoacetamide; BAN, bromoacetonitrile; ${BrO}_{3}^{-}$, bromate; DBBQ, dibromobenzoquinone; FC, fold change; $\log_{2}\text{FC}$, $\log_{2}$ fold changes; $\log_{2}\text{NRQ}$, $\log_{2}\text{-normalized}$ relative quantities; NRQ, normalized relative quantity; ns, not significant; TBAL, tribromoacetaldehyde; TCAA, trichloroacetic acid; TCAL, trichloroacetaldehyde.

*p*-Value for qPCR differential expression based on one-way analysis of variance (ANOVA) with Dunnett's multiple comparison ($n = 3$); *p*-value for microarray expression based on rank product analysis ($n = 2$) in Multiple Experiment Viewer (MeV) suite (version 4.90) for Windows.

The primer set sequences for *HMOX1* were designed using the Primer-BLAST (NCBI) tool ([@c90]) (forward primer: 5′-ACTCCCTGGAGATGACTCCC-3′; reverse primer: 5′-GGGGGCAGAATCTTGCACTT-3′), and for RPL27, adopted from Ersahin et al. ([@c24]) (forward primer: 5′-ATCGCCAAGAGATCAAAGATAA-3′; reverse primer: 5′-TCTGAAGACATCCTTATTGACG-3′). Both primer sets were synthesized commercially (GeneWorks) and evaluated for amplification efficiency (E) (95.8 and 90.5% for HMOX1 and RPL27, respectively).

Hierarchical Clustering and Biological Context Analysis {#s2.7}
-------------------------------------------------------

Agglomerative hierarchical clustering analysis of the DEG data was performed using unweighted pair-group averages and Pearson's correlation coefficient (XLSTAT version 2016 for Windows; Addinsoft).

To investigate biological significance of the identified deregulated genes, we enriched the resulting gene sets, represented by the Illumina gene identifiers ($p \leq \, 0.01$; $\text{FC} \geq \, 1.2$), using tools available in GeneGo's MetaCore bioinformatics suite (version 6.33 build 69110, Clarivariate Analytics; see Supplementary Material for MetaCore output file). From the obtained data, we focused on statistically significant toxicity networks ($p \leq 0.05$). This allowed us to identify a small number of altered biological processes indicative of the mechanisms of toxicity of the selected DBPs.

Quality Assurance and Quality Control {#s2.8}
-------------------------------------

We performed all the exposure tests with careful consideration of *in vitro* quality assurance and quality control measures, which included replicate wells for each of the tested concentrations, at least one independent replicate run on a separate day, multiple cell-free wells to correct for baseline variability and to serve as a negative control for DEG determination, multiple wells containing cell culture media only, and solvent control wells. In addition, we employed nontransformed human cells in order to prevent altered gene expression associated with neoplastic cell lines.

Each RNA extract was tested for purity and integrity using the Agilent 2100 electrophoresis bioanalyzer by the Ramaciotti Centre for Genomics, and only those with RNA integrity numbers $> 8$ were subsequently used in the microarray hybridization ([@c71]) (see [Table 2](#t2){ref-type="table"} for details).

Results {#s3}
=======

Cytotoxicity Assay {#s3.1}
------------------

The 10% inhibition concentration ($\text{IC}_{10}$) values of the $4\text{-}h$ cytotoxicity assay are summarized in [Table 1](#t1){ref-type="table"} (see [Figure 1](#f1){ref-type="fig"} for concentration--effect curves). The $\text{IC}_{10}$ values for each of the tested DBPs were subsequently used in exposure treatments ($4\; h$) of the same cell culture for microarray analysis. As $\text{IC}_{10}$ values ranged over a factor of 10,000, dosing equimolar concentrations would not have yielded comparable gene expression levels. These DBP concentrations and their resulting cytotoxicity in FHs 74 Int cells were highly correlative with the published median lethal concentration ($\text{LC}_{50}$ values using CHO cell cytotoxicity analyses ($r = 0.94$; $p \leq \, 0.001$; $n = 8$) ([@c84]).

Global Gene Expression Microarray Analysis {#s3.2}
------------------------------------------

GE analysis using cDNA microarray revealed that only a small subset of genes was affected by treatment with the selected DBPs at $\text{IC}_{10}$ concentrations. From the total of 47,231 gene probes corresponding to 23,775 genes annotated to Illumina tags (ILMN_ID) by GeneGo's MetaCore, less than 10% were identified as differentially expressed ([Table 1](#t1){ref-type="table"}). A slight dissymmetry toward down-regulation was observed, ranging between 1.1 (DBBQ) and 1.6 (TCAL).

Treatment with BAN resulted in the highest number of DEGs ($p \leq 0.01$; $\text{FC} \geq \, 1.2$), followed by BAA, TBAL, ${BrO}_{3}^{-}$, BAM, DBBQ, TCAA, and, finally, TCAL ([Table 1](#t1){ref-type="table"}). Treatment with Br-DBPs resulted in up to 2-fold higher numbers of DEGs ($p \leq 0.01$) than the chlorine-substituted Cl-DBPs ([Table 1](#t1){ref-type="table"}). All DEGs with $p \leq 0.01$ and $\text{FC} \geq \, 1.2$ were analyzed by hierarchical clustering, and subsequent biological context analysis (i.e., gene and pathway enrichment analysis) was performed with DEGs relevant to each individual cluster group, separately.

The change in *HMOX1* expression upon exposure to the different DBPs in this study was confirmed by qPCR, and both the qPCR and microarray data were in good agreement for this gene (paired *t*-test, $p = 0.87$; [Figure 2](#f2){ref-type="fig"}).

Hierarchical Clustering and Biological Context Analysis {#s3.3}
-------------------------------------------------------

Similarity-based hierarchical clustering identified three main groups ([Figure 3](#f3){ref-type="fig"}): Cluster 1 consisted solely of the two Cl-DBPs (TCAA and TCAL), while Cluster 2 and Cluster 3 incorporated the remaining six Br-DBPs. Cluster 2 contained BAM and DBBQ, and Cluster 3 contained BAA, BAN, ${BrO}_{3}^{-}$, and TBAL ([Figure 3](#f3){ref-type="fig"}).

![Hierarchical clustering of differentially expressed genes (DEGs) based on Pearson similarity coefficient. Cluster 1: TCAA, trichloroacetic acid; TCAL, trichloroacetaldehyde. Cluster 2: BAM, bromoacetamide; DBBQ, dibromobenzoquinone. Cluster 3: BAA, bromoacetic acid; BAN, bromoacetonitrile; ${BrO}_{3}^{-}$, bromate; TBAL, tribromoacetaldehyde.](ehp-127-117006-g003){#f3}

The results of querying GeneGo's toxicity network libraries, using previously identified DEG signatures, were used to assign the biological context of genes and pathways significantly altered by exposure to the studied DBPs. These were subsequently grouped according to the results of hierarchical clustering analysis ([Table 4](#t4){ref-type="table"}). This analysis revealed similarities, but also differences, in altered pathways between the three clusters. While there was evidence of effects on oxidative stress pathways in DBPs from all three clusters, the number of altered genes associated with oxidative stress was much lower than other pathways ([Figure 4](#f4){ref-type="fig"}). Most notably, all three groupings exhibited a comparatively large number of altered genes related to inflammation and immune responses ([Table 4](#t4){ref-type="table"}).

###### 

Cellular processes and associated toxicity networks ($p \leq 0.05$) with up- and down-regulated genes ($p \leq 0.01$), fold change (FC) $\geq \, 1.2$ identified using GeneGo's MetaCore toxicity network enrichment tool.

Table 4 lists cluster number in the first column; the corresponding affected cellular process, dominant toxicity network(s), upregulated genes, and downregulated genes are listed in the other columns.

  Cluster                                    Affected cellular process                                                                           Dominant toxicity network(s)                                                                             Upregulated genes                                                                                              Downregulated genes
  ------------------------------------------ --------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- -------------------------------------------------
  Cluster 1                                  Chemotaxis                                                                                          MAPK cascades                                                                                            *HMOX1, HSP70 (HSPA1A, HSPA1B), CRK, GRP78*                                                                    *IRF1*
  Inflammation/immune response               Antigen presentation/MHC class 1 signaling/MAPK signaling                                           *HMOX1, HSP70, HLA-A, GRP78*                                                                             *IRF1, BDNF*                                                                                                   
  Protein folding                            Unfolded protein response (UPR) via heat shock protein (HSP) 70, HSP90, and p53                     *HSP70 (HSPA1A, HSPA1B, HSPA6), HSP40 (DNAJB1), Aha1 (AHSA1), GRP78*                                     *HSP10* (mitochondrial)                                                                                        
  Apoptosis                                  TNFR signaling                                                                                      *APAF-1*                                                                                                 *BIRC2, BIRC3*                                                                                                 
  Oxidative stress response                  Nrf2 regulation                                                                                     *HMOX1, TXNRD1, GSTM3*                                                                                   ---                                                                                                            
  Cluster 2                                  Inflammation                                                                                        IL-1 pro-inflammatory signalling                                                                         *HMOX1, COX-2, IRAK2, NF-kB, C/EBPbeta, IL-1RI, IL-1b, IL-1a, I-kB (NFKBIA, NFKBIE)*                           *AP-1, endothelin 1 (EDN1)*
  IL-6 receptor anti-inflammatory response   *IL-6, IRAK2, CXCL2, CXCL5, GNA13, NF-kB, HRH1, JAK1, I-kB (NFKBIA, NFKBIE), CXCL1*                 *AP-1, PI3K reg class IA (p85)*                                                                                                                                                                                         
  Chemotaxis                                 MAPK cascades/GRO signaling                                                                         *HSP70 (HSPA6, HSPA1L, HSPA4L, HSPA1A, HSPA1B), HMOX1, IRAK2, IL-1a, IL-1b, IL-1IR, NF-AT2, JAK1, CRK*   *AP-1*                                                                                                         
  Cell cycle dysregulation                   Signaling to E2F                                                                                    *c-Abl (ABL1*)                                                                                           *H2AX, GADD45a, GADD45b, GADD45g, cyclin D, cyclin E, cyclin A, CDC45L, MCM6, MAP3K, AP-1, FEN1, CDK1 (p34)*   
  APC Regulation of G1/S                     *I-kB (NFKBIA, NFKBIE), CDC34*                                                                      *KPNA2, GADD45a, GADD45b, GADD45g, cyclin D, cyclin E, cyclin A, CDC25A, p21, CDK1 (p34)*                                                                                                                               
  Protein folding                            UPR via HSP90                                                                                       *CRYAB, HSP40 (DNAJB1), HSP105 (HSPH1), HSP90AB1, DNAJA1, AHSA1, HSPB8,* HSP70 (HSPA1A)                  ---                                                                                                            
  Apoptosis                                  MAPK cascades (MAPK4 & MAPK9)                                                                       *c-Abl (ABL1), IL-1b, IL-1a, IL-1RI, IRAK2, HMOX1*                                                       *GADD45a, GADD45b, AP-1, endothelin 1 (EDN1), CDK1 (p34)*                                                      
  DNA damage response                        Inhibition of apoptosis, dysregulation of cell cycle, up-regulation of double-stranded DNA repair   *NF-kB*                                                                                                  *CDK1 (p34), AP-1, PCNA, GADD45a, GADD45b*                                                                     
  Cluster 3                                  Inflammation/immune response                                                                        IL-1 pro-inflammatory signaling/IL-6 signaling                                                           *COX-2, HMOX1, IL-1a, IL1-b, NF-kB, IRAK2, C/EBPbeta, IRF1, IL-6, I-kB, IL4R, IL13RA2, JAK1, CXCL2*            *ERK1, AP-1, HMOX1, IL13RA1, PI3K reg class IA*
  Chemotaxis                                 HGF signaling, Cell communication                                                                   *COX-2, CXCL1, EGFR, IL-8, CXCL5*                                                                        *AP-1, PI3K reg class IA, calmodulin*                                                                          
  Cell cycle dysregulation                   Signaling to E2F via cyclin D and cyclin E                                                          *BCAR1, MEKK4 (MAP3K4)*                                                                                  *GADD45b, GADD45a, AP-1, MCM3, cyclin D, cyclin E, CDC45L, PCNA, TCF*                                          
  Signal transduction                        Signaling via IL-1b and IRF1                                                                        *COX-2, IL-1a, IL-1b, HMOX1, NF-kB, IRAK2, IRF1, IFN-α/β receptor, ISG15, CCL5*                          *HMOX1, AP-1, calmodulin*                                                                                      
  Proliferation induction                    PDGF signaling                                                                                      *COX-2, NF-kB p50/RelB, PA24A, PDGF-C*                                                                   *AP-1, ERK1*, calmodulin                                                                                       
  Apoptosis                                  MAPK cascades                                                                                       *IL-1a, IL-1b, IRAK2, MEKK4 (MAP3K4), HMOX1*                                                             *GADD45a, GADD45b, AP-1, HMOX1*                                                                                
  Oxidative stress response                  HNF4 regulation                                                                                     *COX-2, SOD2, HMOX1, TXNRD1, SMAD3*                                                                      *AP-1, PRDX5, HMOX1*                                                                                           

Note: Clusters (outlined in [Figure 3](#f3){ref-type="fig"}) are defined as follows: Cluster 1: TCAA, trichloroacetic acid; TCAL, trichloroacetaldehyde; Cluster 2: BAM, bromoacetamide; DBBQ, dibromobenzoquinone; Cluster 3: BAA, bromoacetic acid; BAN, bromoacetonitrile; ${BrO}_{3}^{-}$, bromate; TBAL, tribromoacetaldehyde. ---, no data; IL, interleukin; MAPK, mitogen-activated protein kinase, Nrf2, nuclear factor (erythroid-derived 2)-like.

![Number of significantly affected GeneGo toxicity networks in 10 functional categories (apoptosis, cell cycle, chemotaxis, DNA damage, protein folding, inflammation and immune response, oxidative stress, cellular processes, signal transduction, and others) for each cluster of disinfection by-products (DBPs). The farther away the section expands from the center of each radar plot, the more toxicity networks were affected (on a scale from 0 to 25). Cluster 1: TCAA, trichloroacetic acid; TCAL, trichloroacetaldehyde. Cluster 2: BAM, bromoacetamide; DBBQ, dibromobenzoquinone. Cluster 3: BAA, bromoacetic acid; BAN, bromoacetonitrile; ${BrO}_{3}^{-}$, bromate; TBAL, tribromoacetaldehyde.](ehp-127-117006-g004){#f4}

Discussion {#s4}
==========

The most recent working hypothesis is that DBPs primarily cause adverse effects through mechanisms related to the production of ROS, which subsequently result in the induction of oxidative stress pathways ([@c73]). Our observation of comparatively few altered genes associated with oxidative stress ([Figure 4](#f4){ref-type="fig"}) is therefore an interesting outcome and potentially very important for understanding DBP toxicity. It was recently proposed that ROS formation is not the sole mechanism of DBP toxicity *per se* ([@c61]), since ROS can arise as a physiological response resulting from other forms of cellular dysfunction caused by chemical insult ([@c65]). Indeed, while it is generally agreed that cells respond to DBPs through pathways sharing ROS-mediated mechanisms ([@c73]; [@c61]; [@c46]), it is becoming clearer that the specific genes associated with oxidative stress involve additional layers of complexity ([@c52]). One key piece of the puzzle therefore involves identifying the functional basis of ROS production elicited by DBP exposure ([@c52]). Untargeted transcriptomic analysis offers a powerful means to broadly identify DBP-responsive genes and thus reveal other deregulations that might be associated with ROS production and the manifestation of oxidative stress responses. Results of the present study offer compelling evidence suggesting a role of pro- and anti-inflammatory response pathways, which we hypothesize forms a significant aspect of the documented cellular injury in DBP-exposed cells.

We observed, in a nontransformed human cell line, FHs 74 Int, the induction of several genes associated with oxidative stress pathways in DBPs from all three clusters, which is consistent with the findings of preceding literature using the same cell line ([@c52]; [@c5]). However, in all cases, the number of DEGs and pathways associated with inflammation and immune responses were by far the most prominent ([Figure 4](#f4){ref-type="fig"}). Clear differences were observed between the less toxic Cl-DBPs (Cluster 1) and more toxic Br-DBPs (Clusters 2 and 3). This may suggest a more complex and mechanistically distinct set of early cellular responses associated with Br-DBPs and supports existing evidence of a lower toxicity risk for their chlorinated analogs ([@c61]; [@c56]; [@c84]). For Br-DBPs in particular, we hypothesize an increased risk of genotoxicity associated with considerable activation of inflammatory responses, for example, characterized by the production of pro-inflammatory (e.g., interleukin 1; IL-1) and anti-inflammatory (e.g., IL-6) cytokines. It is plausible that such responses represent a key mechanism initiating various downstream pathways ([@c77]), including the subsequent generation of ROS ([@c52], [@c53]). Based on concurrent up-regulation of nuclear factor kappa B (Nf-*k*B) and mitogen-activated protein kinase (MAPK) pathways, we speculate that this could involve downstream activation of Toll-like receptors (TLRs) ([@c77]; [@c28]). While it is unlikely that Br-DBPs interact directly with such cellular surface receptors, TLR signaling pathways can be activated by production of pro-inflammatory cytokines ([@c13]), potentially resulting in chronic inflammation and increased production of ROS ([@c45]). The process whereby activation of TLR pathways contributes to tumorigenesis has been relatively well characterized, albeit not in relation to DBP exposure ([@c64]; [@c85]). As indicated, this is merely speculation based on the observed results in relation to existing literature surrounding TLR signaling pathways, and thus, further research is needed to explore this hypothesis and further reveal the mechanistic basis of genotoxicity and potential carcinogenicity related to DBP exposure.

There is a growing realization that inflammatory response pathways are important contributors and regulators of a diverse range of adverse toxicity outcomes ([@c4]; [@c82]). Earlier research has established a strong association between inflammatory networks and ROS production and revealed a high level of interconnectivity that could perpetuate the oxidative damage associated with inflammation responses ([@c65]). Observed activation of anti-inflammatory response pathways alongside the pro-inflammatory response is most likely a result of a feedback mechanism, which, in the absence of additional toxic insult or injury, may ultimately lead to homeostasis and recovery ([@c49]). However, chronic inflammation and oxidative stress may pose an enhanced risk of activating various associated downstream pathways, due to what has been termed a "vicious cycle" of adaptive responsiveness ([@c27]). To clarify, inflammatory responses induce the production of ROS, and the resulting ROS lead to further production of intermediaries that, in turn, induce additional inflammation ([@c65]). Oxidative stress--related xenobiotic-induced ROS production may therefore help explain the various other affected pathways, for example, cell proliferation and regulation of apoptosis ([@c9]).

By increasing cellular level of oxidants, many xenobiotics alter gene expression via activation of cellular signaling pathways, including adenylyl cyclase pathway, calcium-dependent signaling pathways, and transcription factors (TFs) such as nuclear factor (erythroid-derived 2)-like (Nrf2), activator protein 1 (AP-1) and NF-*k*B. Other pathways reportedly influenced by ROS-mediated oxidative stress include altered expression of MAPKs, for example, extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs), and p38 kinases ([@c2]; [@c3]; [@c8]; [@c29]). Indeed, these various pathways are highly consistent with the DBP-responsive genes (most notably for Br-DBPs in Clusters 2 and 3) identified using microarray analysis of FHs 74 Int cells in the present study. Importantly, many of these pathways could be activated either indirectly or directly as a consequence of alterations to genes associated with inflammation and immune responses.

The use of nontransformed human epithelial cells and untargeted transcriptomics highlighted this connection where many other studies have not, probably due to the greater scope for cellular transcriptional responses compared with more targeted transformed cell lines ([@c92]; [@c32]; [@c15]). A recent study using a transformed human uroepithelial cell line (SV-HUC-1) observed increased expression of several Nrf-2 TF-mediated oxidative stress--response genes, including *PTGS2* and *HMOX1* ([@c42]), as did our previous work with Caco-2 cells ([@c52]; [@c61]).

The present study evaluated individual DBPs to explore differences in gene expression and subsequently compare the mechanistic basis of toxicity. One limitation of this study is the lack of PCR confirmation of genes of interest other than *HMOX1*, which we were not able to include due to budgetary constraints. While we do delve into individual DEGs in the discussion, our conclusions are based on analyses of whole pathways, integrative of multiple DEGs, thus providing a degree of resilience against potential occasional inaccuracies in microarray gene expression data. Still, confirmation by qPCR of individual genes affected by exposure to the DBPs highlighted in this study would be warranted in the future.

Future research is now needed to investigate the potential augmented risk associated with the presence of DBPs as complex mixtures ([@c76]; [@c48]; [@c20]; [@c57]). Information regarding chemical mode of action, such as that provided by the present study, is critical for determining whether there is a likelihood of enhanced toxicity due to mixture effects ([@c62]). Despite the identification of three distinct clusters and notable differences between the toxicity and gene expression profiles of Br- and Cl-DBPs, there were similarities in the transcriptional responses of FHs 74 Int cells to all compounds ([Figure 4](#f4){ref-type="fig"}). It is therefore likely that enhanced toxicity might occur from exposure to a mixture compared to individual DBPs ([@c30]; [@c91]). The observed differences between Cl-DBPs and Br-DBPs may suggest unique mechanisms of action for these compounds. However, it is also possible that the lower toxicity of Cl-DBPs allows cells to compensate through protein repair mechanisms (e.g., heat shock proteins), whereas the greater toxicity of Br-DBPs overloaded such compensatory mechanisms, resulting in subsequent activation of other more damaging signaling pathways, including inflammatory responses.

Conclusions {#s5}
===========

Gene expression--based toxicogenomic analysis can be a sensitive and robust tool for comparative assessment of biological activity of chemical compounds. However, several crucial factors must be considered to obtain meaningful data. For example, the provision of $\text{IC}_{10}$ concentrations from cytotoxicity data employing specific and constant exposure times to DBPs at predetermined equipotent concentrations was an important step aimed at reducing the possibility of transcriptome alterations associated with dead or dying cells. Additionally, where many *in vitro* bioassays use tumor cell lines because of their rapid growth and ease of maintenance, nontransformed human cell lines have the added advantage of further avoiding erroneous gene expression profiles associated with neoplastic cell lines. Finally, the FHs 74 Int cell line offers the additional advantage of being very well suited for evaluating effects on immunomodulatory and inflammatory response pathways. With these strengths, our results offer considerable evidence that ROS-mediated oxidative stress pathways may be associated with inflammatory response pathways, which could contribute to a cycle of toxic insult. Considering the well-documented relationship between inflammation and cancer progression, further research exploring this relationship is warranted. Effects of individual DBPs are needed to unravel mechanistic information, but there is clear potential for complex mixtures to occur, and the toxicity of relevant DBP mixtures must be investigated in the future.
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